Get the Stockscreener App
15.44
4.11%
0.61
After Hours:
15.46
0.02
+0.13%
Mesoblast Ltd Adr stock is traded at $15.44, with a volume of 292.52K.
It is up +4.11% in the last 24 hours and up +11.88% over the past month.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
See More
Previous Close:
$14.83
Open:
$15.48
24h Volume:
292.52K
Relative Volume:
1.49
Market Cap:
$2.00B
Revenue:
$65.48M
Net Income/Loss:
$-94.46M
P/E Ratio:
-20.94
EPS:
-0.7375
Net Cash Flow:
$-71.18M
1W Performance:
+7.37%
1M Performance:
+11.88%
6M Performance:
-26.34%
1Y Performance:
+40.11%
1-Day Range:
$15.24
$15.73
1-Week Range:
$13.67
$15.73
52-Week Range:
$10.80
$21.50
Mesoblast Ltd Adr Stock (MESO) Company Profile
Compare MESO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
15.44 | 1.92B | 65.48M | -94.46M | -71.18M | -0.7375 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-25 | Downgrade | Jefferies | Buy → Hold |
| Dec-23-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-24 | Upgrade | Maxim Group | Hold → Buy |
| Aug-29-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-23-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-31-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Downgrade | Maxim Group | Buy → Hold |
| Aug-04-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-04-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-23 | Initiated | William Blair | Outperform |
| Dec-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-06-22 | Initiated | Piper Sandler | Overweight |
| Apr-07-21 | Upgrade | Maxim Group | Hold → Buy |
| Dec-22-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-04-20 | Downgrade | Chardan Capital Markets | Neutral → Sell |
| Oct-22-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-28-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-31-19 | Resumed | H.C. Wainwright | Buy |
| Mar-22-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Feb-28-18 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-31-17 | Initiated | Oppenheimer | Outperform |
| Jun-08-17 | Initiated | Cantor Fitzgerald | Buy |
View All
Mesoblast Ltd Adr Stock (MESO) Latest News
Mesoblast Reports Strong RYONCIL® Revenue, Exceeding Projections - Sharecafe
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 - GlobeNewswire Inc.
8 Health Care Stocks With Whale Alerts In Today’s Session - Sahm
10 Health Care Stocks With Whale Alerts In Today’s Session - Sahm
LWB1 Forecast — Price Target — Prediction for 2027 - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (LSX:A4004R) - TradingView
A4004R Forecast — Price Target — Prediction for 2027 - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (LS:A4004R) - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (NASDAQ:MESO) - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (GETTEX:LWB1) - TradingView
Mesoblast Ltd consensus and trial focus, shares watched on Nasdaq - ad-hoc-news.de
ON Semiconductor, SanDisk And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - Benzinga
MESO - Finviz
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
Mesoblast LimitedDepositary Receipt (MESO) price target decreased by 14.96% to 15.33 - msn.com
Mesoblast completes enrollment in back pain therapy trial - Investing.com
Mesoblast acquires CAR technology license from Mayo Clinic - Investing.com
FDA clears Mesoblast DMD trial for Ryoncil in children - Investing.com
Mesoblast drops after Ryoncil sales data for March quarter - Seeking Alpha
MESO Ignites 10% Surge: A Biotech Spark Ignited Without a Visible Fuse - Bitget
Philip Krause details Mesoblast (NASDAQ: MESO) share and option holdings - Stock Titan
Mesoblast issues 5 million unquoted warrants as fee for US$50 million convertible note facility - MSN
Mesoblast Ltd Stock (ISIN: AU000000MSB8) Faces Pressure as Director Buys Signal Confidence Amid Anal - AD HOC NEWS
Gregory George beneficial owner at Mesoblast (OTC: MEOBF) with 22.36% stake - Stock Titan
MEOBF SEC FilingsMesoblast 10-K, 10-Q, 8-K Forms - Stock Titan
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Sahm
Earnings call transcript: Mesoblast’s strong Q1 2026 performance boosts outlook - Investing.com
FARM 51 GROUP S.A.ZY -,1.XFRA: MWBMUHANDELSUNTERBRECHUNGTEIL 5 - aktiencheck.de
Mesoblast (NASDAQ: MESO) holders may resell 500,000 ADSs via warrants - Stock Titan
Mesoblast stock reaches 52-week high at 21.05 USD - Investing.com
Mesoblast stock reaches 52-week high at 21.05 USD By Investing.com - Investing.com India
Mesoblast (ASX:MSB) Delivers 60% Jump in Ryoncil Sales, Strengthening Commercial Momentum - Stocks Down Under
Mesoblast announces board leadership changes as company evolves - Investing.com South Africa
Mesoblast Issues 5 Million Unquoted Warrants as Fee for US$50 Million Convertible Note Facility - TipRanks
Mesoblast Shares (ASX:MSB) Stall at Resistance After Recent Rally - thebull.com.au
Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Jefferies upgrades Mesoblast stock to Buy on strong Ryoncil sales - Investing.com
Insights: Mesoblast Ltd (ASX:MSB) - smallcaps.com.au
Mesoblast rides early ryoncil® momentum, tightens cash discipline, and prepares for next growth phase - Proactive financial news
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket - Benzinga
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mesoblast secures up to US$50m in fresh funding through convertible note agreements - Biotech Dispatch
Mesoblast Secures Up To US$50 Mln In Convertible Note Agreements With Key Investors - Nasdaq
Canaccord Genuity initiates Mesoblast stock with Buy rating on cell therapy potential - Investing.com
Mesoblast stock soars after reporting first Ryoncil sales By Investing.com - Investing.com South Africa
Mesoblast Ltd (MSB) Stock Forecast & Analyst Ratings - Moomoo
MESO SEC FilingsMesoblast 10-K, 10-Q, 8-K Forms - Stock Titan
All Markets & Instruments Available to Trade - Capital.com
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Sahm
Mesoblast Ltd Adr Stock (MESO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):